Birch Triterpenes Suppliers & Bulk Manufacturers
Available Forms: Topical Gel
Available Strengths: 10% w/w
Reference Brands: Filsuvez (USA/EU)
Category:
Derma Drugs
Birch Triterpenes is available in Topical Gel
and strengths such as 10% w/w.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Birch Triterpenes is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Birch Triterpenes can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Birch triterpenes, marketed under the brand name Filsuvez, is a topical medication derived from the bark of silver birch (Betula pendula) and downy birch. It is specifically formulated for the treatment of partial-thickness skin wounds in patients with epidermolysis bullosa, a rare inherited condition that causes extremely fragile skin, severe blistering, and scarring. The active components are pentacyclic triterpenes extracted from birch bark, which promote wound healing, protect damaged skin, and support the regeneration of the upper layers of the skin.
Filsuvez is indicated for use in individuals aged six months and older with dystrophic epidermolysis bullosa and junctional epidermolysis bullosa, targeting wounds where the epidermis has been partially damaged. The formulation leverages the natural healing properties of birch triterpenes to accelerate recovery, reduce pain, and minimize the risk of infection in affected areas. Recognized by the U.S. Food and Drug Administration as a first-in-class medication, Filsuvez represents a breakthrough in the management of epidermolysis bullosa, offering patients a safe, effective, and non-invasive option to improve skin integrity and quality of life.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing